Oncopeptides AB (publ) (ONCO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Oncopeptide's year-end earnings call for 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Sophia Hagas and CFO Henrik Bergentoft. Please go ahead. Hello everyone and welcome to the presentation of Oncopeptide's year-end report for 2025. My name is Sofia Hegis and I'm the CEO of the company. Before we begin, I would like to direct your attention to our standard disclaimer regarding forward-looking statements. I am joined by our CFO, Henrik Bergentoft, and today we will review a highly transformative year for the company and outline a 2026 that brings exciting potential. Let's look at where we stand today. As we have already communicated, we delivered strong commercial progress in 2025, with full year net sales more than doubling to 71.1 million SEK, representing a 125% increase compared to 2024. For the fourth quarter, net sales reached 18.6 million SEK, an 88% increase compared to the same period in 2024. We have today also announced a rights issue of up to 200 million SEK, allowing us to invest in the first step to expand our PDC platform into the high unmet need of glioblastoma patients. An opportunity that comes with the potential to unlock significant value for both patients and oncopeptides in the future. The rights issue will furthermore bridge our commercial operations towards our goal of positive cash flow in 2027. Henrik will discuss this in more detail shortly. The fourth quarter was shaped by a diverse performance in our key markets. The demand for pipaxity in Italy exceeded our expectations. Our positive growth trajectory during...